NCT00068315 - Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2003

Primary Completion Date

December 31, 2008

Conditions

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueHematopoietic/Lymphoid CancerNodal Marginal Zone B-cell LymphomaRecurrent Adult Diffuse Small Cleaved Cell LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic LeukemiaSplenic Marginal Zone LymphomaWaldenström Macroglobulinemia

Interventions

DRUG

bortezomib

Given IV

DRUG

fludarabine phosphate

Given IV

BIOLOGICAL

rituximab

Given IV

Trial Locations (7)

44106

Case Western Reserve University, Cleveland

Seidman Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland

44121

University Suburban Medical Center, South Euclid

44122

UHHS-Chagrin Highlands Medical Center, Orange

44130

Southwest General Health Center Ireland Cancer Center, Middleburg Heights

44145

UHHS-Westlake Medical Center, Westlake

44708

Mercy Medical Center, Canton

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH